Item 8.01. Other Events.

On October 18, 2021, Lucid Diagnostics Inc. (the "Company") consummated the initial public offering ("IPO") of 5,000,000 shares of its common stock, par value $0.001 per share ("Common Stock"). The shares of Common Stock were offered to the public through an underwriting syndicate acting on a firm commitment basis. The Common Stock was sold at a public offering price of $14.00 per share, generating gross proceeds of $70,000,000.

The underwriters for the offering received discounts and commissions equal to 7.0% of the aggregate purchase price of the Common Stock sold in the offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from the Company at the initial public offering price less underwriting discounts and commissions.

Cantor and Canaccord Genuity are acting as joint book-running managers for the offering. BTIG and Needham & Company are acting as co-lead managers for the offering.

A copy of the press release issued by the Company announcing the consummation of the IPO is included as Exhibit 99.1 to this Current Report on Form 8-K.

© Edgar Online, source Glimpses